K Number
K192447
Manufacturer
Date Cleared
2020-02-28

(175 days)

Product Code
Regulation Number
888.3030
Reference & Predicate Devices
Predicate For
N/A
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
Intended Use

The Superelastic Staple are indicated for hand and foot bone fragments osteotomy fixation and joint arthrodesis.

Device Description

The Superelastic Staple consists of staples available in several lengths. All the implants are made of NiTi alloy.

AI/ML Overview

The provided text describes a 510(k) premarket notification for a medical device called the "Superelastic Staple." This document focuses on demonstrating substantial equivalence to predicate devices through non-clinical testing. It explicitly states that no clinical studies were performed.

Therefore, it is not possible to provide the requested information regarding acceptance criteria and a study proving the device meets those criteria, as no clinical performance data for the device's efficacy or accuracy is presented in the provided document.

The document details the following regarding the device and its assessment:

  • Device Name: Superelastic Staple
  • Regulation Number: 21 CFR 888.3030 (Single/multiple component metallic bone fixation appliances and accessories)
  • Regulatory Class: Class II
  • Product Code: JDR
  • Indications for Use: The Superelastic Staple is indicated for hand and foot bone fragments osteotomy fixation and joint arthrodesis.
  • Predicate Devices:
    • Biopro Memory Staples® (K061798) from Biopro (Primary)
    • Memometal Memory Staples (Memoclip – Easy Clip – For Fusion) (K070031) from Memometal
    • ARCAD Compressive Osteosynthesis Staple, EXPRESS Compressive Osteosynthesis Staple (K142111) from Novastep
  • Device Description: Made of NiTi alloy per ASTM F2063.
  • Non-Clinical Tests Performed:
    • Static bending test (ASTM F564 – Annex 4)
    • Dynamic bending test (ASTM F564 Annex 1)
    • Axial pull-out strength (ASTM F564 Annex 2)
    • Transition temperature (ASTM F2004)
    • Corrosion susceptibility testing (ASTM F2129)
    • Cytotoxicity testing (ISO 10993-5:2009)
    • Acute Systemic Toxicity testing (ISO 10993-11:2006)
    • Chemical Characterization (ISO 10993-18:2005)
  • Clinical Test Summary: "No clinical studies were performed."

Given this, I cannot fill out the requested table or answer the specific questions about clinical study design, acceptance criteria, sample sizes, expert involvement, or ground truth, as that information is not part of this 510(k) submission. This document relies solely on non-clinical (mechanical and biocompatibility) testing to demonstrate substantial equivalence.

{0}------------------------------------------------

February 28, 2020

Image /page/0/Picture/1 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

Neosteo % J.D Webb Official Correspondent The OrthoMedix Group, Inc. 4313 W. 3800 S West Haven, Utah 84401

Re: K192447

Trade/Device Name: Superelastic Staple Regulation Number: 21 CFR 888.3030 Regulation Name: Single/multiple component metallic bone fixation appliances and accessories Regulatory Class: Class II Product Code: JDR Dated: January 28, 2020 Received: January 30, 2020

Dear J.D Webb:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{1}------------------------------------------------

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely.

FOR Vesa Vuniqi Acting Assistant Director DHT6A: Division of Joint Arthroplasty Devices OHT6: Office of Orthopedic Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known)

K192447

Device Name

Superelastic Staple:

Indications for Use (Describe)

The Superelastic Staple are indicated for hand and foot bone fragments osteotomy fixation and joint arthrodesis.

Type of Use (Select one or both, as applicable)

ا Prescription Use (Part 21 CFR 801 Subpart D)

_ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

Image /page/3/Picture/1 description: The image shows the logo for Neosteo Efficient Mobility. The logo consists of an orange spiral design on the left, resembling a stylized eye or gear. To the right of the spiral is the word "neosteo" in orange, with the words "EFFICIENT MOBILITY" in smaller, black font underneath. The logo appears to be for a company involved in efficient transportation solutions.

510(k) Summary

l. SUBMITTER'S INFORMATION

A. 510(k) Owner

NEOSTEO Mallève 2A 1 Boulevard Jean Moulin 44 100 Nantes, France Tel: +33 (0)2 36 56 96 70 Fax: +33 (0)2 51 70 61 34

B. Contact Person

JD Webb The Orthomedix Group, Inc. 4313 W. 3800 S. West Haven, UT 84401 Tel: 512 590-5810 Email: jdwebb@orthomedix.net

C. Date of Preparation of the 510(k) Summary

August 30, 2019

{4}------------------------------------------------

Image /page/4/Picture/1 description: The image shows the logo for Neosteo. The logo consists of an orange spiral design on the left and the word "neosteo" in orange on the right. Below "neosteo" is the phrase "EFFICIENT MOBILITY" in a smaller, lighter font. The spiral design is made up of a series of lines radiating from a central orange circle.

510(k) Summary

II. DEVICE IDENTIFICATION

Trade or proprietary nameSuperelastic Staple
Common or usual nameBone Staple
Classification regulation21 CFR 888.3030
Proposed Regulatory ClassClass II
Panel87 "Orthopedic"
Product codeJDR
Primary Predicate DeviceBiopro Memory Staples® (K061798) from Biopro
Reference Predicate DevicesMemometal Memory Staples (Memoclip – Easy Clip – For Fusion) (K070031) fromMemometal
ARCAD Compressive Osteosynthesis Staple, EXPRESS Compressive Osteosynthesis Staple(K142111) from Novastep

lll. DEVICE DESCRIPTION

The Superelastic Staple consists of staples available in several lengths. All the implants are made of NiTi alloy.

A. Materials

Superelastic Staple: NiTi alloy per ASTM F2063

{5}------------------------------------------------

Image /page/5/Picture/1 description: The image shows the logo for Neosteo Efficient Mobility. The logo consists of an orange spiral design on the left, resembling a stylized eye or gear. To the right of the spiral is the word "neosteo" in orange, with the words "EFFICIENT MOBILITY" in smaller letters underneath. The logo appears to be for a company involved in efficient transportation solutions.

510(k) Summary

IV. INTENDED USE

The Superelastic Staple are indicated for hand and foot bone fragments osteotomy fixation and joint arthrodesis.

V. SUMMARY OF TECHNOLOGICAL CHARACTERISTICS / SUBSTANTIAL EQUIVALENCE

The Superelastic Staple is substantially equivalent to the predicate devices in terms of intended use, design, materials used, mechanical safety and performances.

VI. NON-CLINICAL TEST SUMMARY

The following mechanical tests were performed:

  • о Static bending test according to ASTM F564 – Annex 4
  • Dynamic bending test according to ASTM F564 Annex 1 O
  • Axial pull-out strength according to ASTM F564 Annex 2 O
  • Transition temperature according to ASTM F2004 O
  • Corrosion susceptibility testing according to ASTM F2129 o
  • Cytoxicity testing according to ISO 10993-5:2009 O
  • Acute Systemic Toxicity testing according to ISO 10993-11:2006 O
  • Chemical Characterization according to ISO 10993-18:2005 O

The results of these tests indicate that the Superelastic Staple are equivalent to predicate device.

VII. CLINICAL TEST SUMMARY

No clinical studies were performed.

CONCLUSIONS NON-CLINICAL AND CLINICAL VIII.

NEOSTEO considers the Superelastic Staple to be equivalent to the predicate devices listed above. This conclusion is based on the devices' similarities in principles of operation, technology, materials and indications for use.

§ 888.3030 Single/multiple component metallic bone fixation appliances and accessories.

(a)
Identification. Single/multiple component metallic bone fixation appliances and accessories are devices intended to be implanted consisting of one or more metallic components and their metallic fasteners. The devices contain a plate, a nail/plate combination, or a blade/plate combination that are made of alloys, such as cobalt-chromium-molybdenum, stainless steel, and titanium, that are intended to be held in position with fasteners, such as screws and nails, or bolts, nuts, and washers. These devices are used for fixation of fractures of the proximal or distal end of long bones, such as intracapsular, intertrochanteric, intercervical, supracondylar, or condylar fractures of the femur; for fusion of a joint; or for surgical procedures that involve cutting a bone. The devices may be implanted or attached through the skin so that a pulling force (traction) may be applied to the skeletal system.(b)
Classification. Class II.